AstraZeneca continues to build out its presence in China with new COPD drug manufacturing site

According to a press release, translated from Chinese, AstraZeneca officially announced it will expand its investment in China and plans to spend some cash to construct a production and supply base as well, as a regional headquarters in the port city of Qingdao, Shandong in eastern China. Qingdao will also be home to an innovation center focused on rare diseases, a life science innovation park and an industrial fund.